PURMX Therapeutics is a startup from Hiroshima University that aims to develop new drugs based on natural microRNAs. The company is developing anti-tumor drugs through an innovative approach to kill cancer cells by turning on the "aging switch" by replenishing aging-inducing microRNAs which lack in cancer cells, and is currently conducting Phase I clinical trials for malignant pleural mesothelioma. By conducting global clinical trials and expanding the indications of the products, the company aims to provide new treatment options for refractory cancers with no effective treatments and to become a global leader in the field of microRNA drug development.